Key result
Higher serum asprosin correlates with insulin resistance in PCOS with an AUC of ~0.83.
Why the study?
Dysregulation of adipokines may play a role in the development of PCOS, and the relationship between asprosin and insulin resistance in PCOS patients was unclear.
Are serum asprosin levels associated with insulin resistance in patients with polycystic ovary syndrome?
Case-Control (n=426)
Are serum asprosin levels associated with insulin resistance in patients with polycystic ovary syndrome?
Effect estimate: AUC 0.826 (95% CI 0.724-0.879)
p-value: p=<.05
Increased serum asprosin levels are independently associated with PCOS and may serve as a novel biomarker for evaluating insulin resistance in this population.
May support asprosin as IR biomarker in PCOS; hypothesis-generating and requires prospective validation.
Dysregulation of adipokines may play a role in the development of polycystic ovary syndrome (PCOS). This was a retrospective case-control study to investigate the relationship between asprosin and insulin resistance in patients with PCOS patients. The study enrolled 213 PCOS patients and 213 age-matched and body mass index-matched controls. The serum asprosin levels and the relationship between asprosin and PCOS with IR were compared between the 2 groups. In the current study, it was found that the serum asprosin level and hemostasis of model assessment-insulin resistance of PCOS were significantly higher than those of the control group, and asprosin was independently correlated with hemostasis of model assessment-insulin resistance and CRP (P < .05). Asprosin was found to be statistically significant in the analysis of receiver operating characteristics, and the specific result was 0.826 (0.724-0.879). This study emphasizes that increased levels of asprosin are independently associated with PCOS, and asprosin may be a new indicator for evaluating insulin resistance in PCOS patients.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) conducted a case-control in Polycystic ovary syndrome (PCOS) (n=426). Serum asprosin levels vs. Age- and BMI-matched controls was evaluated on Serum asprosin level and insulin resistance (HOMA-IR) (AUC 0.826, 95% CI 0.724-0.879, p=<.05). Serum asprosin levels were significantly elevated in patients with polycystic ovary syndrome and independently correlated with insulin resistance (AUC 0.826; 95% CI 0.724-0.879).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: